Rapport den 16 / 05

IDEX 14.05.2024 kl 07:44 1796

VISA Certifieringen?
15.05.2024 kl 18:00 1644

The Company is publishing its Q1 2024 report on 16 May 2024. The highlights from the report are summarized below:

First quarter achievements:

Bank launch announcements with IDEX Pay in Asia and Europe
DenizBank, Turkey
Mutual Trust Bank, Bangladesh
Issuer with solution for visually impaired, UK
Opening new market in South Asia with challenger bank
Mobile enrolment SDK solution in market
Market expansion of IDEX Access with AuthenTrend and Sentry
Large South Asian card manufacturing partner for IDEX Pay and IDEX Access
Biometric metal cards with CompoSecure


Revenues in the first quarter of 2024 were 0.4 mill USD compared to 1.2 mill USD in Q1 2023. Revenues in the first quarter of 2024 continue to reflect the transition from component to solution sales.
Gross margin was 36% in the first quarter.
Operating expenses, excluding cost of materials, in the first quarter of 2024 was 6,1 mill USD compared to 7.7 mill USD in the first quarter of 2023.
Cash balance as of 31 March 2024 was 3.0 mill USD
15.05.2024 kl 18:02 1641

The Private Placement:

The subscription price per Offer Share in the Private Placement (the "Offer Price") and the number of Offer Shares to be issued in the Private Placement will be determined by the board of directors of the Company (the "Board") following an accelerated bookbuilding process. The bookbuilding period commences today at 16:30 CEST and ends at 08:00 CEST on 16 May 2024. The bookbuilding period may, at the discretion of the Company and the Manager, close earlier or later and may be cancelled at any time and, consequently, the Company may refrain from completing the Private Placement.

The Company will announce the final number of Offer Shares placed and the final Offer Price in a stock exchange announcement expected to be published before the opening of trading on the Oslo Stock Exchange tomorrow, 16 May 2024.

The Private Placement will be directed towards Norwegian and international investors, in each case subject to applicable exemptions from relevant prospectus, filing or other registration requirements. The minimum application and allocation amount in the Private Placement will be the NOK equivalent of EUR 100,000, provided that the Company may, at its sole discretion, allocate an amount below EUR 100,000 to the extent applicable exemptions from relevant prospectus and registration requirements pursuant to applicable regulations, including Regulation (EU) 2017/1129 (the EU Prospectus Regulation) and ancillary regulations, are available.

The Private Placement will be divided into two tranches. Tranche 1 will consist of 28,012,655 Offer Shares (representing approximately 10% of the outstanding shares in the Company) ("Tranche 1" and the "Tranche 1 Offer Shares"). Tranche 2 will consist of up to the number of Offer Shares that, together with the Tranche 1 Offer Shares, is necessary in order to raise gross proceeds of NOK 40-50 million ("Tranche 2" and the "Tranche 2 Offer Shares"). Allocations of Offer Shares to investors are expected to be split between Tranche 1 and Tranche 2 on a pro rata basis. Completion of Tranche 2 will be subject to approval by an extraordinary general meeting of the Company expected to be held on or about 12 June 2024 (the "EGM").

The subscribers in the Private Placement will without cost be allocated one warrant (Nw. "frittstående tegningsrett") issued by the Company for every Offer Share allocated to, and paid by, them in the Private Placement. Each warrant will give the holder a right to subscribe for one new share in the Company at a subscription price equal to the Offer Price in the Private Placement. The warrants may be exercised during four exercise periods: (i) within the first 14 days after the Company's announcement of its first half 2024 financial report (expected on 15 August 2024), (ii) within the first 14 days after the Company's announcement of its Q3 2024 financial report (expected on 14 November 2024), (iii) within the first 14 days following the Company's announcement of its Q4 2024 financial report (expected on 27 February 2025), and (iv) within the first 14 days following the Company's announcement of its Q1 2025 financial report (expected mid-May 2025). Following expiry of the last exercise period, all Warrants not exercised will lapse without compensation to the holder. The Warrants will be registered in the VPS but will not be transferable or tradable. Issuance of Warrants is subject to approval by the EGM. In addition, issuance of Warrants for Tranche 1 Offer Shares and Tranche 2 Offer Shares, respectively, is subject to satisfaction of the other conditions for completion of the respective tranches

Allocation of Offer Shares will be determined by the Board at its sole discretion, in consultation with the Manager, following the expiry of the bookbuilding period, however subject to approval by the EGM in respect of Tranche 2 (and the Warrants). Allocation will be based on criteria such as (but not limited to) pre-indications, perceived investor quality, existing ownership in the Company, timeliness of the application, price leadership, relative order size, sector knowledge, investment history and investment horizon. The Board may, at its sole discretion, reject and/or reduce any applications, and there is no guarantee that any applicant will be allocated Offer Shares. Notification of allocation and payment instructions are expected to be issued to the applicants on or about 16 May 2024 through a notification to be issued by the Manager.

Completion of Tranche 1 is subject to (i) approval by the Board and (ii) the Share Lending Agreement (as defined below) remaining in full force and effect. Completion of Tranche 2 is subject to (i) completion of Tranche 1, (ii) approval by the EGM and (iii) the Share Lending Agreement remaining in full force and effect. Further to this, completion of both Tranche 1 and Tranche 2 are subject to the Company resolving to consummate the Private Placement and allocate the Offer Shares. Completion of Tranche 1 will not be conditional upon or otherwise affected by the completion of Tranche 2 and/or the warrant issuance, and the applicants' acquisition of Tranche 1 Offer Shares will remain final and binding and cannot be revoked, cancelled or terminated by the respective applicants if Tranche 2 and/or the warrant issuance, for whatever reason, is/are not completed. Investors being allocated shares in the Private Placement undertake to vote in favour of Tranche 2, the warrant issuance and any resolution related to a subsequent offering (as further described below) at the EGM.

Both Tranche 1 and Tranche 2 will be settled with existing and unencumbered shares in the Company that are already listed on the Oslo Stock Exchange, pursuant to a share lending agreement expected to be entered into between the Company, the Manager and certain existing shareholders (the "Share Lending Agreement"). The share loan in Tranche 1 will be settled with new shares in the Company to be resolved issued by the Board pursuant to an authorisation by the Company’s extraordinary general meeting held on 21 December 2023. The share loan in Tranche 2 will be settled with new shares in the Company expected to be issued following, and subject to, approval by the EGM. The new shares to be redelivered to the lenders under the Share Lending Agreement will, to the extent required, be delivered on a separate and non-tradable ISIN, pending publication by the Company of a listing prospectus approved by the Norwegian Financial Supervisory Authority.

Settlement of the Tranche 1 Offer Shares is expected to take place on a delivery versus payment basis on or about 22 May 2024. Settlement of the Tranche 2 Offer Shares is expected to take place on a delivery versus payment basis on or about 14 June 2024, subject to approval by the EGM.
The Company reserves the right, at any time and for any reason, to cancel, and/or modify the terms of, the Private Placement prior to delivery of the Tranche 1 Offer Shares. Furthermore, Tranche 2 will be cancelled if the conditions for completion of Tranche 2 are not satisfied. Neither the Company nor the Manager will be liable for any losses incurred by applicants if the Private Placement is cancelled, irrespective of the reason for such cancellation.

The Board has considered the Private Placement in light of the equal treatment obligations under the Norwegian Public Limited Companies Act, the Norwegian Securities Trading Act, the rules on equal treatment under Oslo Rule Book II for companies listed on the Oslo Stock Exchange and the Oslo Stock Exchange's Guidelines on the rule of equal treatment, and deems that the proposed Private Placement is in compliance with these requirements. The Board holds the view that it will be in the common interest of the Company and its shareholders to raise equity through a private placement, in view of the current market conditions and the funding alternatives currently available to the Company. A private placement enables the Company to raise capital in an efficient manner, and the Private Placement is structured to ensure that a market-based subscription price is achieved. The Company is of the view that the discount in a rights issue would have to be quite significant, and that a rights issue would need to be guaranteed by a consortium of underwriters, which would entail an added cost for the Company. By structuring the equity raise as a private placement, the Company is expected to be in a position to raise capital at a better share price, at a lower cost and with significantly lower risk than in a rights issue.

The Company may, subject to completion of the Private Placement, approval from the EGM and certain other conditions, consider to carry out a subsequent repair offering of new shares at the Offer Price directed towards existing shareholders in the Company as of 15 May 2024 (as registered in the VPS on 21 May 2024), who were not allocated Offer Shares in the Private Placement and who are not resident in a jurisdiction where such offering would be unlawful or, for jurisdictions other than Norway, would require any prospectus, filing, registration or similar action.
Slettet bruker
15.05.2024 kl 18:53 1550

Boken lukket på 1,65.
15.05.2024 kl 18:55 1542

1,65 er ikke dumt!
Slettet bruker
15.05.2024 kl 19:03 1514

Blir liten rabatt når de lokker med warrants.
15.05.2024 kl 19:07 1497

Slettet bruker skrev Boken lukket på 1,65.
Det var god pris. Supert.
15.05.2024 kl 19:20 1448

Så det var derfor kursen raste. Dette har nok ligget på trappene en stund og innsidere har fått solgt ut litt.

IDEX var fullfinansiert ut året og etter aksjespleisen i januar droppa kursen nesten til det halve og ATL. Selv da stod shorten og ingen innsidere kjøpte. De har også lenge signalisert at mye skulle skje på slutten av fjordåret og første kvartal i år, men det var knapt lyd i selskapet. Dette skjer vel for fjerde år på rad mens de henter penger.

Men det kan være et godt tegn her, at de vil unnggå lånet på 100 mll som noen noe feilaktig har kalt et døsspirallån, men fortsette de slik som de foregående årene burde vi samle inn meldingene som ofte er vage og muligens få noen med hode eller myndighet til å gå igjennom dette. Er avtalene gode, eller er det avtaler du kan kjøpe av en korrupt banksjef, el, og hvor det med liten skrift som vi aldri ser gjør at de kan trekke seg sånn uten videre?

Jeg sier ikke at det er slik og håper enda på det beste. Ting tar ofte mye lengre tid enn man forutser og mye har skjedd i verden de senere år. Likevel vil det være lett og jukse med slikt om man ønasker det.
Redigert 15.05.2024 kl 19:22 Du må logge inn for å svare
15.05.2024 kl 19:25 1438

IDEX FULLFINANSIERT UT 2024 (Finansavisen 15. nov. 2023)
Med emisjon på inntil 35 millioner kroner, en ikke-bindende avtale med det selskapet omtaler som en ny institusjonell investor for utstedelse av en konvertibel obligasjon på inntil 100 millioner kroner, samt redusere kostnadene for å oppnå en kvartalsvis driftskostnadsnivå på omtrent 4 millioner dollar, forventer selskapet å være fullfinansiert ut 2024,» heter det.
22.05.2024 kl 07:07 634

This notice is issued by IDEX Biometrics ASA on behalf of the shareholder mentioned below.

IDEX Biometrics ASA disclosed on 15 May 2024 that it had conducted a private placement of 33.3 million new shares in IDEX Biometrics. Tranche 1 of the private placement amounted to 27.9 million shares. In connection with the private placement, the managers of the private placement, IDEX Biometrics and certain existing shareholders entered into a share lending agreement.

Mr. Robert Keith participated in the private placement and subscribed for 3,619,380 shares in Tranche 1. Mr. Keith has also lent 17,940,213 shares in connection with the settlement of the private placement. The shares have been lent, not sold, and will be returned in due course. After the temporary disposal of shares, Mr. Keith and close relations hold 16,770,266 shares or rights to shares or 5.4% of the total outstanding shares and votes in IDEX Biometrics after completion of Tranche 1.
22.05.2024 kl 10:21 318

Sidelengs idag også. Klarer man å bryte den sterke falltrenden?

Aksjen har støtte ved cirka 1.28 kroner og motstand ved cirka 1.87 kroner. RSI under 30 viser at momentumet i aksjen er sterkt negativt på kort sikt. Investorer har stadig gått ned i pris for å få solgt aksjen, noe som indikerer økende pessimisme og at kursen skal fortsette ned. (Investtech)

Det er vel gjerne litt sterkere gjennomslag for tekniske signaler uten nyheter?

Ser jo hvordan man må ned i kurs for å bli kvitt volum. Men volumet totalt sett ser ut til å minke. Slik det også gjorde rundt forrige bunn i mars.
Det blir gjerne en slags gjentagelse?
Redigert 22.05.2024 kl 10:25 Du må logge inn for å svare